Abstract: The invention relates to a method for producing a mesenchymal stem cell (MSC), the method comprising culturing a primitive mesoderm cell in a mesenchymal colony forming medium (M-CFM) comprising LiCl and FGF2, but excluding PDGF, under normoxic conditions for sufficient time for a mesenchymal colony to form, and culturing the mesenchymal colony adherently to produce the MSC, wherein the MSC has superior T-cell immunosuppressive properties relative to an MSC not produced in said M-CFM. The invention also relates to an MSC produced by the method, a population of MSCs produced by the method, a therapeutic composition comprising the MSC produced by the method, an M-CFM and an M-CFM in concentrated form, and method and uses of the MSC or population in treating a disease.
Type:
Grant
Filed:
March 14, 2017
Date of Patent:
November 16, 2021
Assignee:
Cynata Therapeutics Limited
Inventors:
Igor Slukvin, Gene Uenishi, Derek Hei, Diana Drier
Abstract: In related-art methods of differentiating pluripotent stem cells into a desired cell type, there has not been established a differentiation induction method using human ES/iPS cells and being stable and highly efficient. The use of complicated culture steps is a large problem. In addition, there are also large problems in, for example, that the speed of cell differentiation is low, and hence long-period culture is required, and that the differentiation efficiency is low, and hence it is difficult to obtain a sufficient number of required cells. A method of inducing differentiation into a desired cell type, which induces differentiation within a short period of time and with high efficiency by the use of a Sendai virus vector capable of expressing a transcription factor, and as required, the use of a pluripotent stem cell in which an expression amount of a POU5F1 protein has been substantially removed or reduced, is provided.
Abstract: A Thy1 gene promoter specifically expressed in neurons and a recombinant vector including the Thy1 gene promoter are provided. The Thy1 gene promoter may be utilized to regulate an expression of a target gene in preparation of an animal model similar to a human.
Type:
Grant
Filed:
April 6, 2017
Date of Patent:
September 14, 2021
Assignee:
Jeju National University Industry-Academic Cooperation Foundation
Inventors:
Se Pill Park, Young Sok Choi, Ok Hee Lee, Mi Seon Park, Young Ho Kim, Eun Young Kim, Seung Eun Lee
Abstract: This invention relates to viral vectors for delivery of alpha-L-iduronidase to the cornea of a subject and methods of using the same for treatment and prevention of corneal clouding and blindness in a subject due to mucopolysaccharidosis I.
Type:
Grant
Filed:
February 22, 2017
Date of Patent:
September 14, 2021
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Matthew Louis Hirsch, Richard Jude Samulski
Abstract: The present invention relates to a dermal layer which is for grafting and has an improved graft survival rate, and a method for producing the same, wherein the dermal layer for grafting can be produced by filling a filling solution, including a DNA fragment mixture and chitosan, into an acellular dermal matrix from which cells have been removed. It was observed that the dermal layer for grafting produced in this manner, due to the filling solution filled therein and including a DNA fragment mixture and chitosan, increases the rate at which cells flow in from the tissue surrounding the graft and are fixed, and thereby alleviates an initial inflammatory reaction and promotes blending with the surrounding tissue.
Abstract: The present invention relates to the field of stem cells. More specifically, the present invention provides methods and compositions useful for the highly efficient conversion of human stem cells to lineage-specific neurons. In a specific embodiment, a method of inducing differentiation of human stem cells into dopaminergic (DA) neurons comprises the steps of (a) transfecting human stem cells with a lentiviral vector encoding Atoh1, wherein the vector is Dox inducible; and (b) growing the transfected cells in culture in the presence of Dox, Sonic Hedgehog (SHH) and FGF-8b until DA neurons are induced.
Abstract: The invention relates to mammalian haploid embryonic stem cells and methods for the production of such stem cells. The inventions also relates to a cell culture and a cell line of mammalian haploid embryonic stem cells.
Abstract: Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.
Type:
Grant
Filed:
April 9, 2019
Date of Patent:
July 27, 2021
Assignee:
FATE THERAPEUTICS, INC.
Inventors:
Bahram Valamehr, Ramzey Abujarour, Tom Tong Lee, Weijie Lan, Raedun Clarke, Ryan Bjordahl
Abstract: Non-human animals suitable for use as animal models for Retinoschisis are provided. In some embodiments, provided non-human animals are characterized by a disruption in a Retinoschisin-1 locus. In some embodiments, provided non-human animals are characterized by a mutant Retinoschisin-1 gene. The non-human animals may be described, in some embodiments, as having a phenotype that includes the development of one or more symptoms or phenotypes associated with Retinoschisis. Methods of identifying therapeutic candidates that may be used to prevent, delay or treat Retinoschisis or eye-related diseases, disorders or conditions are also provided.
Type:
Grant
Filed:
February 26, 2018
Date of Patent:
July 20, 2021
Assignee:
REGENERON PHARMACEUTICALS, INC.
Inventors:
Susannah Brydges, Yajun Tang, Yang Liu, Jingtai Cao, Carmelo Romano
Abstract: An immortalized sweat gland myoepithelial cell which expresses ?-SMA and pan-cytokeratin and has a sphere forming ability after subculture at least 5 times. A method for producing immortalized sweat gland myoepithelial said method comprising: while culturing a cell structure, wherein sweat gland myoepithelial cells are exposed on a surface, in a state of being suspended in a medium, transferring an immortalizing gene into the cells; and then culturing the transgenic structure thus obtained in a state of being suspended in the medium to thereby obtain immortalized sweat gland myoepithelial cells.
Abstract: The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.
Abstract: A flowable birth tissue composition fabricated from birth tissue is provided. Methods of processing a mammal's placental tissue to form a flowable birth tissue composition are provided. Various methods of treatment and uses are also provided.
Abstract: A transgenic non-human mammal containing a heterologous heavy chain gene locus that is capable of producing soluble heavy chain only antibodies and antigen-binding fragments thereof following immunization.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
May 4, 2021
Assignee:
ERASMUS UNIVERSITY MEDICAL CENTER
Inventors:
Franklin Gerardus Grosveld, Richard Wilhelm Janssens
Abstract: The disclosure relates to Bovine germplasm of Bos taurus variety HO840M003150607238. Included in the present disclosure are cells comprising the genome of Bovine variety HO840M003150607238 characterized by the presence of homozygous loci and spermatozoa obtained from said cells. Also provided by the present disclosure are tissue cultures of cells, animals obtained from said cells, and parts thereof, including F1 spermatozoa. The disclosure further provides for methods of breeding, selecting, and using the germplasm to improve existing commercial cattle herds generated from in vitro fertilization methods and progeny cattle obtained from in vitro fertilization and implantation and artificial insemination methods.
Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
Abstract: The disclosure relates to Bovine germplasm of Bos taurus variety JE840003146074527. Included in the present disclosure are cells comprising the Bovine variety JE840003146074527. Also provided by the present disclosure are tissue cultures of cells, animals obtained from said cells, and parts thereof, including F1 spermatozoa. The disclosure further provides for methods of breeding, selecting, and using the germplasm to improve existing commercial cattle herds generated from in vitro fertilization methods and progeny cattle obtained from in vitro fertilization and implantation and artificial insemination methods.
Abstract: Described herein are methods and compositions related to induced alveolar epithelial type 2 cells (iAEC2s), e.g., artificially-produced epithelial type 2 cells.
Abstract: The disclosure provides methods of generating a murine model of neonatal necrotizing enterocolitis, whereby the generated murine animal exhibits at least one symptom of neonatal necrotizing enterocolitis. The disclosure also provides methods to measure transfusion effects on anemia and methods for identifying and isolating an agent useful for the treatment or prevention of neonatal necrotizing enterocolitis.